ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0512

Factors Associated with Treatment Pathways in Early Axial Spondyloarthritis: A Multistate Analysis of the 10-year Follow-up of the DESIR Cohort

Elodie Portier1, Sylvie chevret2, Adeline Ruyssen-Witrand3, Anouk Walter-Petrich2, Maxime Dougados4 and Anna Molto5, 1Hôpital Cochin, Paris, France, 2Saint Louis Hospital, Paris, France, 3Toulouse University Hospital, Toulouse, France, 4Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris, Paris, France, 5HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France

Meeting: ACR Convergence 2023

Keywords: Epidemiology, Spondyloarthropathies, Statistical methods

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0510–0542) Spondyloarthritis Including Psoriatic Arthritis – Treatment: AxSpA Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Current recommendations for the management of patients with axial spondyloarthritis (axSpA) emphasize the need of individualized strategy in the therapeutic decision. Thus, many factors seem to impact this strategy.

The objectives of the study were to describe the therapeutic strategies observed in axSpA, and to assess the factors associated with treatment changes over time.

Methods: This study included patients with axSpA from the French prospective cohort DESIR, with a scheduled 10-year follow-up. A multi-state model with 4 ordered treatment states (“none”, “non-steroidal anti-inflammatory drugs (NSAID)”, “conventional synthetic DMARD (csDMARD)”, “TNF inhibitors (TNFi)”) was defined, with 6 possible transitions. Estimation of the restricted mean sojourn times spent in each state from the state occupation probabilities was performed. Then, predictors of those transitions were assessed by multivariable Cox models.

Results: 686 (96.9%) of the 708 patients who had more than one visit were analyzed. At cohort entry, 199 (29.0%) were untreated, 427 (62.2%) received NSAID, and 60 (8.7%) received csDMARD and none TNFi.

Over the 10 years of follow-up, patients mostly received NSAID (46.4% of the time) followed by TNFi (24.4% of the time). In multivariable analysis (figure), presence of sacroiliitis on radiography, internal bowel disease and articular index were associated with transition to NSAID. Duration in the previous state was often a significant protective factor associated with transition to csDMARD or TNFi. Finally, the several disease activity outcomes were associated with most transitions.

Conclusion: This was the first study using a multistate model to easily represent the different states, detailing the transitions across them, and their associated factors. Different time profiles of axSpA patient management were identified, including abstention up to a significant proportion of patients treated with csDMARD.

Supporting image 1

Figure: Multistate model representation. Each arrow corresponds to a possible transition (n=6). Number at baseline denotes the number of patients who started from the state at baseline. The number of events and factors significantly associated with each transition in the multivariable analysis are written near to the corresponding arrow.
NSAID refers to non-steroids anti-inflammatory drugs, csDMARD stands for conventional synthetic Disease Modifying Anti-Rheumatic Drug, and TNFi for tumor necrosis factor inhibitors.


Disclosures: E. Portier: None; S. chevret: None; A. Ruyssen-Witrand: None; A. Walter-Petrich: None; M. Dougados: AbbVie, 2, 5, Bristol Myers Squibb, 2, 5, Eli Lilly, 2, 5, MSD, 2, 5, Novartis, 2, 5, Pfizer Inc, 2, 5, Roche, 2, 5, UCB, 2, 5; A. Molto: None.

To cite this abstract in AMA style:

Portier E, chevret S, Ruyssen-Witrand A, Walter-Petrich A, Dougados M, Molto A. Factors Associated with Treatment Pathways in Early Axial Spondyloarthritis: A Multistate Analysis of the 10-year Follow-up of the DESIR Cohort [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/factors-associated-with-treatment-pathways-in-early-axial-spondyloarthritis-a-multistate-analysis-of-the-10-year-follow-up-of-the-desir-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/factors-associated-with-treatment-pathways-in-early-axial-spondyloarthritis-a-multistate-analysis-of-the-10-year-follow-up-of-the-desir-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology